Suggestions on how to assess risk and manage bone issues in chronic kidney disease patients are offered…
Zoledronate After Denosumab Does Not Fully Prevent Bone Loss
NEW YORK (Reuters Health)—In postmenopausal women and men treated for at least two years with denosumab, a single infusion of zoledronate given after denosumab discontinuation does not completely prevent bone turnover and loss, researchers say. Given the findings, “bone mineral density (BMD) should probably be higher than the current target for discontinuation of bisphosphonate treatment…
After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk
(Reuters Health)—Patients hospitalized for a hip fracture are less likely to experience a subsequent fracture-related hospitalization if they start anti-osteoporosis medication sooner, a Taiwanese study suggests.1 Researchers examined data on 77,930 patients aged 50 years and older hospitalized for hip fractures, including 9,986 people prescribed anti-osteoporosis medications within one year of the index fracture. Compared…
Coding Corner Answers: An Office Personnel Quiz
Take the challenge. D. When an infusion is ordered by the provider, there should be a signed order from the provider. If a prior authorization is needed, it should be obtained, with the number of infusions, along with the start and end dates of the authorization. Also, a prior authorization does not guarantee reimbursement; an…
Coding Corner Questions: An Office Personnel Quiz
A 65-year-old male patient diagnosed with rheumatoid arthritis at multiple sites without rheumatoid factor has been ordered to have infliximab infusions. What should support staff do to ensure this procedure can be given to the patient? Make sure there is a signed order from the provider Make sure a prior authorization is obtained Make sure…
Premenopausal Osteoporosis Poses Special Clinical Challenges
ATLANTA—Osteoporosis in premenopausal women is uncommon compared with its frequency in post-menopausal women, but when it is suspected, it poses some difficult questions for clinicians: How should it be diagnosed in this understudied population? If found, should it be treated—and how? Elizabeth Shane, MD, professor of medicine at Columbia University and attending physician at New…
Denosumab Tied to Infection Risk
NEW YORK (Reuters Health)—The osteoporosis drug denosumab is associated with a higher incidence of serious infections compared with placebo, but the risk is similar to comparator drugs, a systematic review and meta-analysis reveals. Talia Diker-Cohen, MD, PhD, of Tel Aviv University, and colleagues searched the literature through May 2019 for randomized controlled trials of denosumab…
If It’s Broken, Fix It: Can an Automated System Predict Short-Term Fracture Risk?
A clinician’s ability to determine which patients are at greatest risk for hip or other fracture is improving with the use of algorithm-based fracture risk calculators…
High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost
NEW YORK (Reuters Health)—Adding high-dose teriparatide to denosumab therapy leads to substantially greater increases in bone-mineral density (BMD) than combination therapy with low-dose teriparatide, a new phase 4 study shows. “The combination of denosumab and teriparatide, particularly with high-dose teriparatide of 40 ug daily, may be of benefit to patients at very high risk of…
Osteoporosis Drugs Don’t Reduce Overall Mortality
NEW YORK (Reuters Health)—Anti-fracture medications do not reduce overall mortality in older patients with osteoporosis, according to an updated systematic review and meta-analysis. “This meta-analysis suggests drug treatments, including treatment with bisphosphonates, for osteoporosis should be recommended only for the prevention of fracture and not for any additional reduction in mortality,” researchers write in JAMA…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 19
- Next Page »